Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

BACKGROUND: Ribociclib (RIBO) and palbociclib (PALBO), combined with letrozole (LET), have been evaluated as treatments for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in separate Phase III randomized controlled trials (RCTs), but not head-to-h...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Chandiwana, David, Dolph, Mike, Hearnden, Jaclyn, Forsythe, Anna, Monaco, Mauricio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968783/
https://www.ncbi.nlm.nih.gov/pubmed/29861642
http://dx.doi.org/10.2147/CMAR.S163478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968783/
https://www.ncbi.nlm.nih.gov/pubmed/29861642
http://dx.doi.org/10.2147/CMAR.S163478

Ejemplares similares